Oryzon Genomics (ORY) Q4 2024 earnings summary

Executive summary

• Oryzon Genomics reported a net loss of €3.67M for the year ended 31/12/2024, slightly higher than the €3.35M loss in 2023.

• Total assets increased to €108.7M from €106.9M year-over-year, driven by higher intangible assets.

• Cash and cash equivalents declined to €5.6M from €12.3M at year-end 2023.

Financial highlights

• Revenue for the year was €7.36M, down from €14.19M in 2023.

• Operating loss (EBIT) was €4.42M, a slight improvement from €4.55M in the prior year.

• Net financial loss was €1.15M, compared to €1.56M in 2023.

• Cash flow from operations was negative €5.69M, a significant deterioration from negative €0.58M in 2023.

• Investment outflows totaled €7.81M, mainly for intangibles.

Capital allocation and financing

• Equity increased to €87.0M from €81.8M, reflecting capital increases and new share issues.

• Financial debt (long and short term) totaled €16.3M, down from €18.5M in 2023.

• No dividends were paid in 2024 or 2023.